Recent Updates
Recently added Catalysts

Colorectal Cancer: 7 biotech companies competing in the clinic

OncologyKnife fightData as of 2026-09-04

Competitors7in the clinic
Median market cap$723Muniverse median $1.20B
Allocated capital$5.9B$33.0B competing
Phase 3 or filed31 mid, 3 early
Pure plays0this indication only
Capital rank30/299crowding rank 18

Colorectal Cancer is one of the more crowded fields on the map: 7 companies in the clinic, ranking it 18th of 299 indications by competitor count. The median competitor is worth $723M, below the $1.20B median of the universe.

That gap is the crowding discount. When a field is deep the market pays less per company, because the same eventual revenue has to be split across more shots on goal.

3 of the 7 are in Phase 3 or filed, and 7 dated catalysts fall in the next 12 months, so this ranking is likely to move.

$5.9B of allocated capital sits in Colorectal Cancer, ranking it 30th of 299 indications by the money committed to it.

Companies developing drugs for Colorectal Cancer 7

TickerCompanyLead assetPhaseTrialsMarket capPure playIndicationsNext catalyst
EXELExelixisXL092Phase 33$14.7BNo11 3 Dec 2026
SMMTSummit TherapeuticsivonescimabPhase 34$13.7BNo5 14 Nov 2026
AGENAgenusBotensilimabPhase 36$371MNo7 31 Dec 2026
VSTMVerastemVS-7375Phase 21$723MNo8 31 Dec 2026
IMNMImmunome1617Phase 11$3.1BNo2 31 Dec 2026
LYELLyell ImmunopharmaLYL273Phase 11$351MNo3 31 Dec 2026
DTILPrecision BioSciencesCEA-targeted CAR-T cellsPhase 12$203MNo16 31 Dec 2026

Sorted by phase, then by market capitalisation. Ticker links open the company profile. EXEL holds 44% of the $33.0B competing in this indication.

Why Colorectal Cancer is a knife fight

Crowded and cheaply priced. Six or more competitors and a median company below the universe median.

The map splits indications on two folds: six or more competitors counts as crowded, and a median company above $1.20B counts as richly priced. Colorectal Cancer has 7 competitors and a median of $723M.

Oncology

Oncology holds $187B of the map's capital, 27.8% of the total, spread across 119 indications and 103 companies. 34 of those indications have more than one company competing.

See every Oncology indication on the map

Related indications in Oncology

Head and Neck Cancer7 companies · $5.5B · median $1.8BGold rushOvarian Cancer9 companies · $6.7B · median $1.4BGold rushSmall Cell Lung Cancer8 companies · $6.7B · median $2.0BGold rushAcute Myeloid Leukemia15 companies · $7.0B · median $1.2BKnife fightBiliary Tract Cancer4 companies · $4.6B · median $7.4BConcentrated betWell-differentiated Non-functional Neuroendocrine Tumor1 company · $4.5B · median $9.0BUncontestedHepatocellular Carcinoma5 companies · $7.3B · median $2.1BConcentrated betChronic Lymphocytic Leukemia4 companies · $3.7B · median $2.1BConcentrated bet

Colorectal Cancer pipeline questions

Which biotech companies are developing drugs for Colorectal Cancer?

7 US-listed companies in the $100M to $20B market cap band run clinical programmes in Colorectal Cancer. The largest and most advanced are Exelixis (EXEL, XL092, Phase 3); Summit Therapeutics (SMMT, ivonescimab, Phase 3); Agenus (AGEN, Botensilimab, Phase 3); Verastem (VSTM, VS-7375, Phase 2); Immunome (IMNM, 1617, Phase 1). The full list of 7 is in the table on this page.

How advanced is the Colorectal Cancer pipeline?

Of the 7 clinical-stage programmes in Colorectal Cancer, 3 are in Phase 3 or filed, 1 is in mid-stage development and 3 are in early-stage development.

How much is the typical Colorectal Cancer biotech company worth?

The median company developing a drug for Colorectal Cancer is worth $723M, against a median of $1.20B across the whole universe. $5.9B of allocated capital sits in the indication, ranking it 30th of 299.

When is the next Colorectal Cancer catalyst?

The next dated catalyst in Colorectal Cancer is SMMT on 14 Nov 2026. 7 dated events across the field fall in the next 12 months.

How this page is built

  • Universe is US-listed drug developers with a $100M to $20B market capitalisation, identified by SEC SIC code 2833, 2834 or 2836 or by a pharmaceutical or biotechnology industry classification, less a reviewed exclusion list of contract research organisations, device and diagnostics makers and diversified generics manufacturers.
  • An asset attributed to three or more different companies is treated as shared standard of care rather than any one company’s programme and excluded. Pembrolizumab alone appears under 21 tickers in raw trial data.
  • A programme counts only where at least one industry-sponsored trial supports it, so investigator-initiated academic studies of third-party drugs are excluded.

Allocated capital divides each company’s market capitalisation evenly across the indications it is running clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe.

Third-party market size estimates are not used anywhere on this page. Approved incumbents are excluded from competitor counts, and companies above $20B are outside the universe by construction.

Back to the disease map